Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RITALIN: 123 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
123
Total FAERS Reports
7 (5.7%)
Deaths Reported
23
Hospitalizations
123
As Primary/Secondary Suspect
3
Life-Threatening
5
Disabilities

First Report: 19940405 · Latest Report: 20140528

What Are the Most Common RITALIN Side Effects?

#1 Most Reported
Drug ineffective
13 reports (10.6%)
#2 Most Reported
Feeling abnormal
10 reports (8.1%)
#3 Most Reported
Abnormal behaviour
9 reports (7.3%)

All RITALIN Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Drug ineffective 13 10.6% 0 1
Feeling abnormal 10 8.1% 1 0
Abnormal behaviour 9 7.3% 0 0
Agitation 7 5.7% 0 2
Depression 6 4.9% 0 0
Fatigue 6 4.9% 0 2
Insomnia 6 4.9% 0 0
Intentional drug misuse 6 4.9% 0 0
Suicidal ideation 6 4.9% 1 1
Confusional state 5 4.1% 0 3
Hypertension 5 4.1% 0 2
Pain 5 4.1% 0 3
Wrong technique in drug usage process 5 4.1% 1 0

Who Reports RITALIN Side Effects? Age & Gender Data

Average age: 27.5 years. Most reports from: US. View detailed demographics →

Is RITALIN Getting Safer? Reports by Year

YearReportsDeathsHosp.
2003 1 0 0
2008 3 1 1
2009 1 0 0
2010 4 0 0
2011 1 0 0
2012 8 1 2
2013 23 1 8
2014 14 0 3

View full timeline →

What Is RITALIN Used For?

IndicationReports
Attention deficit/hyperactivity disorder 52
Product used for unknown indication 9
Disturbance in attention 6
Off label use 6

RITALIN vs Alternatives: Which Is Safer?

RITALIN vs RITLECITINIB RITALIN vs RITODRINE RITALIN vs RITONAVIR RITALIN vs RITUXAN RITALIN vs RITUXIMAB RITALIN vs RITUXIMAB-ABBS RITALIN vs RITUXIMAB-ARRX RITALIN vs RITUXIMAB-PVVR RITALIN vs RIVAROXABAN RITALIN vs RIVASTIGMINE

Official FDA Label for RITALIN

Official prescribing information from the FDA-approved drug label.